clinical trial · NCT07321912
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center·phase2·recruiting·n = 406
OsteosarcomaEwing SarcomaEwing Sarcoma MetastaticEflornithineTopotecanCyclophosphamideVincristineDoxorubicinIfosfamideEtoposideCisplatin
brief summary
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
started
Jun 5, 2026
primary completion
Jun 1, 2031
completion
Jun 1, 2036
last updated
Jun 12, 2026
official title
A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol